INDEMNIFICATION AGREEMENTIndemnification Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ______________, 20__, between NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
NGM BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestor Rights Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of March 20, 2015, by and among NGM BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and the holders of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock (the “Prior Investors”) listed on Exhibits A, B, C and D hereto, and MERCK SHARP & DOHME CORP. (the “Purchaser”). The Prior Investors and the Purchaser are referred to hereinafter as the “Investors” and each individually as an “Investor.”
NGM BIOPHARMACEUTICALS, INC. OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)Option Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, NGM Biopharmaceuticals, Inc. (the “Company”) has granted you an option under its 2008 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
NGM BIOPHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for David J. Woodhouse, Ph.D.Executive Employment Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (“Agreement”) is effective as of January 28, 2015, by and between David J. Woodhouse, Ph.D. (“Executive”) and NGM Biopharmaceuticals, Inc. (the “Company”).
CONFIDENTIALMulti-Product License Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
RESEARCH COLLABORATION, PRODUCT DEVELOPMENT AND LICENSE AGREEMENT by and between NGM BIOPHARMACEUTICALS, INC. and MERCK SHARP & DOHME CORP.Research Collaboration, Product Development and License Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Research Collaboration, Product Development and License Agreement (this “Agreement”) is effective as of February 18, 2015 (the “Execution Date”), and is entered into by and between NGM BIOPHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“NGM”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of Delaware (“Merck”). Each of Merck and NGM may be referred to herein individually as a “Party” and collectively as “Parties.”
March 20, 2015 NGM Biopharmaceuticals, Inc. South San Francisco, CA 94080 Re: Letter Agreement Ladies and Gentlemen:Letter Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • California
Pursuant to that certain Series E Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated February 18, 2015, by and between Merck Sharp & Dohme Corp. (“Merck”) and NGM Biopharmaceuticals, Inc. (the “Company”), Merck and the Company agree to be legally bound to the terms set forth below. Reference is made to the Research Collaboration, Product Development and License Agreement dated February 18, 2015, by and between Merck and the Company (the “Collaboration Agreement”). Capitalized but undefined terms used herein shall have the meaning set forth in the Collaboration Agreement.
NGM BIOPHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for William J. RieflinExecutive Employment Agreement • September 28th, 2018 • NGM Biopharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (“Agreement”) is effective as of September 30, 2010, by and between William J. Rieflin (“Executive”) and NGM Biopharmaceuticals, Inc. (the “Company”).
